

ASX Announcement

16 October 2023

Antisense Therapeutics to Participate in Upcoming Industry Conferences

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], a biotechnology company focused on the development of novel therapies for rare diseases, is pleased to provide details of its planned participation in several key upcoming industry conferences.

The company's involvement in these events represents part of an ongoing strategic commitment to proactively engage with prospective investors and partners, and to focus those efforts primarily on Australia and the United States.

Investors and potential partners who would like to meet with the company at any of these events are invited to consult the respective websites for registration information.

BIO Investor Forum

17-18 October 2023 | San Francisco, CA

Antisense CEO, Dr James Garner, will present to US investors and potential partners at the BIO Investor Forum in San Francisco, CA, at 1:45pm, PT, on Tuesday 17 October 2023 (7:45am, AEDT, on Wednesday 18 October). The presentation will substantially rely on the corporate deck released to ASX on 28 August 2023, and so the company does not anticipate a separate release of presentation materials.

AusBiotech Annual Conference

1 – 3 November 2023 | Brisbane, QLD

Antisense personnel will be in attendance at the AusBiotech annual conference, which is held this year in Brisbane, QLD from 1-3 November 2023.

Biotech Showcase

8 – 10 January 2024 | San Francisco, CA

Company executives will attend the Biotech Showcase conference, held in parallel to the JP Morgan Healthcare Conference, from 8-10 January 2024 in San Francisco, CA.

The JP Morgan conference, and associated events, constitute the largest life sciences industry conference in the world, and provide critical opportunities for companies to network with potential partners and investors.

~ ENDS ~

This announcement has been authorised for release by the Board.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial in non-ambulant subjects with DMD.

For more information, please contact info@antisense.com.au